Empowering confident cancer care at every step
Myriad Oncology offers comprehensive germline and tumor genomic tests that provide clinically actionable insights, helping to tailor treatments for each patient’s unique cancer journey—maximizing their chance for a healthier future.
Improving patients outcomes throughout their journey
From risk assessment to therapy selection, Myriad Oncology offers integrated germline and tumor genomic tests that enable a truly personalized approach to cancer prevention and treatment.
Comprehensive support services for providers and patients
Myriad Oncology provides a comprehensive suite of services and workflow solutions that simplify germline and tumor genomic testing, all at no additional cost to the clinic or patient.
Comprehensive support services for providers and patients
Myriad Oncology provides a comprehensive suite of services and workflow solutions that simplify germline and tumor genomic testing, all at no additional cost to the clinic or patient.
Myriad Oncology empowers providers and patients with fast, comprehensive answers to guide management decisions and targeted therapy choices
Comprehensive germline and tumor genomic biomarker testing from a single, trusted source
-
Germline Tests
![](data:image/svg+xml;utf8,<svg xmlns="http://www.w3.org/2000/svg" width="108" height="40"></svg>)
Germline hereditary cancer test that evaluates 48 clinically actionable genes to provide a comprehensive, guideline-driven assessment across 11 common cancer sites.
-
Tumor Profiling
![](data:image/svg+xml;utf8,<svg xmlns="http://www.w3.org/2000/svg" width="292" height="65"></svg>)
Precise Tumor® is a pan-cancer, comprehensive laboratory test that uses state-of-the-art, next-generation sequencing to discover and target important variants within tumors.
-
Genomic prognostic test for patients newly diagnosed with early-stage, estrogen-receptor-positive, HER2-negative breast cancer.
-
Prolaris® is a molecular diagnostic test that helps determine the aggressiveness of a prostate cancer tumor to guide the best treatment decisions for prostate cancer patients.
-
HRD Status
The most comprehensive FDA-approved tumor test that determines HRD status in women with ovarian cancer.
-
![](data:image/svg+xml;utf8,<svg xmlns="http://www.w3.org/2000/svg" width="243" height="40"></svg>)
FDA-approved germline companion diagnostic test for patients with breast, ovarian, pancreatic and prostate cancer.
-
IHC Stains
FDA-approved assay to identify patients with ovarian cancer who may qualify for treatment with mirvetuximab*
-
Offered together with Precise Tumor™ to measure protein expression and identify patients who may benefit from immunotherapy
Affordable genetic testing
Latest research and publications
Groundbreaking research to support patient health
Myriad conducts industry-leading, innovative genetic research and testing to further the science of care. Our scientific studies have been published in prominent journals and at global conferences and feature breakthrough insights for improved patient treatments and outcomes.
See our publicationsReferences:
- Gradishar W, et al. Clinical variant classification: a comparison of public databases and a commercial testing laboratory. The Oncologist. 2017; 22(7):797–803. doi: 10.1634/theoncologist.2016-0431
- Mundt E, et al. Driving Down the Rate of Variants of Uncertain Significance as the Myriad MyRisk® Multigene Panel Grows [White paper]. Myriad Genetics. Oct 2019.
- Internal data on file at Myriad Genetics, Inc
Myriad Genetics, MyRisk, Precise Tumor, MyChoice, Prolaris, BRACAnalysis CDx, RiskScore, and their respective logos, are registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions. EndoPredict and the EndoPredict logo are either trademarks or registered trademarks of Eurobio Scientific.
